Myeloma-Developing Regimens Using Genomics (MyDRUG)

NCT03732703 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

103

Enrollment

NETWORK

Sponsor class

Conditions

Relapsed Refractory Multiple Myeloma

Interventions

DRUG: Abemaciclib, dexamethasone, ixazomib, pomalidomide
DRUG: Enasidenib, dexamethasone, ixazomib, pomalidomide
DRUG: Cobimetinib, dexamethasone, ixazomib, pomalidomide
DRUG: Erdafitinib, dexamethasone, ixazomib, pomalidomide
DRUG: Venetoclax, dexamethasone, ixazomib, pomalidomide
DRUG: Daratumumab, dexamethasone, ixazomib, pomalidomide
DRUG: Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide
DRUG: Selinexor, dexamethasone, ixazomib, pomalidomide

Sponsor

Multiple Myeloma Research Consortium

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]